Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis (Q44065007)

29 November 2017

Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis (English)

1 reference

29 November 2017

Louise McHugh

1

1 reference

29 November 2017

Stella Hu

2

1 reference

29 November 2017

B K Lee

3

1 reference

29 November 2017

Kenneth Santora

4

1 reference

29 November 2017

Paul E Kennedy

5

1 reference

29 November 2017

Edward A Berger

6

1 reference

29 November 2017

Ira Pastan

7

1 reference

29 November 2017

Dean H Hamer

8

1 reference

29 November 2017

language of work or name

English

0 references

publication date

15 July 2002

1 reference

Journal of Biological Chemistry

29 November 2017

1 reference

29 November 2017

277

1 reference

29 November 2017

34383-34390

1 reference

29 November 2017

37

1 reference

Toward HIV eradication or remission: the tasks ahead.

29 November 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Latent reservoirs of HIV: obstacles to the eradication of virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

The challenge of viral reservoirs in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Reservoirs for HIV infection and their persistence in the face of undetectable viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Therapeutic potential of anti-HIV immunotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

21 January 2018

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Recombinant immunotoxins for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

Rationale for the use of immunotoxins in the treatment of HIV-infected humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M205456200

21 January 2018

Identifiers

DOI

10.1074/JBC.M205456200

1 reference

29 November 2017

1 reference